Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic schistosomiasis.

Karin L Andersson1, Raymond T Chung

  • 1Karin L. Andersson, MD, MPH Gastrointestinal Unit, Massachusetts General Hospital, GRJ7, 55 Fruit Street, Boston, MA 02114, USA. kandersson@partners.org.

Current Treatment Options in Gastroenterology
|January 29, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Gender Differences in Colonoscopy: Implications for Clinical Practice and Female Gastroenterologists.

Digestive diseases and sciences·2021
Same author

The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence.

Hepatology (Baltimore, Md.)·2021
Same author

Type I, II, and III interferon signatures correspond to COVID-19 disease severity.

medRxiv : the preprint server for health sciences·2021
Same author

A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.

Hepatology (Baltimore, Md.)·2021
Same author

Loss of Coordinated Neutrophil Responses to the Human Fungal Pathogen, <i>Candida albicans</i>, in Patients With Cirrhosis.

Hepatology communications·2021
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Praziquantel remains the primary treatment for schistosomiasis due to its effectiveness and affordability. While praziquantel resistance is a concern, no significant efficacy loss has been observed to date.

Area of Science:

  • Tropical medicine
  • Infectious diseases
  • Pharmacology

Background:

  • Schistosomiasis is a significant parasitic disease globally.
  • Praziquantel is the cornerstone treatment for schistosomiasis, valued for its efficacy, safety, and cost-effectiveness.
  • Concerns exist regarding potential praziquantel resistance, although widespread use has not yet shown significant efficacy decline.

Purpose of the Study:

  • To review the current status of praziquantel as the gold standard treatment for schistosomiasis.
  • To discuss the implications of potential praziquantel resistance and its impact on schistosomiasis management.
  • To outline therapeutic goals, including parasite eradication and reduction of chronic complications like hepatic fibrosis.

Main Methods:

  • Literature review of praziquantel efficacy and resistance in schistosomiasis treatment.

Related Experiment Videos

  • Analysis of treatment outcomes, including cure rates and management of chronic complications.
  • Evaluation of therapeutic strategies for hepatic schistosomiasis and portal hypertension.

    • Main Results:

    • Praziquantel is highly effective, with most patients clearing infection after one or two courses.
    • Mild to moderate hepatic fibrosis associated with schistosomiasis is often reversible with successful treatment.
    • Advanced hepatic fibrosis and portal hypertension are irreversible, with variceal bleeding being a major cause of mortality.

    Conclusions:

    • Praziquantel remains the most effective and accessible treatment for schistosomiasis.
    • Management of chronic hepatic schistosomiasis focuses on preventing irreversible complications and managing variceal bleeding.
    • Careful consideration of surgical interventions is necessary in patients with advanced hepatic schistosomiasis to avoid complications.